bioAffinity
  • Home
  • Publications
  • News
  • About Us
  • Videos
  • Contact
  • Investor Relations
  • Careers
Select Page

bioAffinity Technologies Presents Scientific Discoveries Advancing Cancer Therapeutics and Diagnostics at Two Global Conferences

by Maria Zannes | Jun 23, 2021 | Events, Press Releases

JUNE 23, 2021 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held biotech company, will present the Company’s discoveries in the field of cancer diagnostics and therapeutics at the RNA Therapeutics Institute’s 2021 RNA Therapeutics Symposium June 23 – 25,...

Dr. David Elzi will present the poster “Selective Cancer Cell Killing by Dual siRNA Knockdown of CD320 and LRP2 Receptors” at the UMASS RNA Therapeutics Symposium

by Maria Zannes | Jun 8, 2021 | Events

Dr. Elzi will present his poster “Selective Cancer Cell Killing by Dual siRNA Knockdown of CD320 and LRP2 Receptors” at the University of Massachusetts RNA Therapeutics Symposium:  From Concept to Clinic, June 23-25, 2021.  Dr. Elzi’s live presentation will...

Fed change in cancer screening could nearly double SA biotech’s growth

by Maria Zannes | Mar 20, 2021 | Articles, News

Local CEO: New recommendations acknowledge that women and Black people are at higher risk than white men MARCH 19, 2021 As published in the San Antonio Business Journal By: W. Scott Bailey – Senior Reporter, San-Antonio Business Journal Several major national medical...

Leading Cell Biology Journal Publishes bioAffinity Technologies’ Groundbreaking Research on Porphyrins

by Maria Zannes | Mar 3, 2021 | Press Releases

MARCH 3, 2021 (SAN ANTONIO, TX) Peer-Reviewed Paper Explains How Porphyrins Used in Company’s Diagnostic and Therapeutic Platforms Enter Cancer Cells bioAffinity Technologies, a privately held company focused on early diagnostics and cancer therapeutics, announced...

Dr. David Elzi will present the poster “Meso-tetra (4-carboMeso-tetra (4-carboxyphenyl) porphyrin (TCPP) is taken up in cancer cells by the CD320 receptor” at ICPP-11

by Maria Zannes | Feb 16, 2021 | Events

Dr. David Elzi will present the poster “Meso-tetra (4-carboMeso-tetra (4-carboxyphenyl) porphyrin (TCPP) is taken up in cancer cells by the CD320 receptor” at the International Conference on Porphyrins and Phthalocyanines (ICPP) ICPP-11 virtual from June 26 through...
« Older Entries
Next Entries »

Categories

  • Articles (27)
  • Events (38)
  • News (52)
  • Press Releases (127)
  • Publications (17)

Recent Posts

  • Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging July 9, 2025
  • bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference June 26, 2025
  • bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy June 24, 2025
  • bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas’ Leadership Board June 11, 2025
  • bioAffinity Technologies Works With Cardinal Health™ OptiFreight® Logistics to Help Meet Demand for CyPath® Lung June 3, 2025

Learn About CyPath Lung

CyPath Lung Test

Main Menu

  • Home
  • Publications
  • News
  • About Us
  • Videos
  • Contact
  • Investor Relations
  • Careers
Copyright © 2023 bioAffinity Technologies, Inc.